Last night, we increased Livy’s new seizure medication to the next level in the titration process. We are hopeful that getting her up to the recommended dose will reduce some of the recent seizure activity we have seen. There are small signs that introducing the new med is helping but we’re still not sure. It could just be Livy going through some type of cycle.
Medicine is supposed to be a science but there is still much guess work that goes into it. Regardless if it is epilepsy, cancer, depression, or other types of disorders and syndromes, doctors, many times, have no idea how people will react to a specific medicine.
The field of science has made extraordinary advancements in the area of genetic testing that can offer insight into how people may respond to medications. But there are still many unknowns. This will likely change dramatically as scientists becomes more proficient and additional mutations are associated with certain diseases.
Of course insurance companies must come to grips that covering the cost of the tests will save them money in the long run. We are still far from that realization in the majority of cases. We have to get to a point where these tests become the norm for immediately establishing if there is an underlying condition that responds better to one treatment over another.
Like many scientific practices of the past, the “Wait and See” methodology will one day be out of vogue. For now, it will continue to be a widely excepted practice. Unfortunately, with complicated illnesses and many unknowns, there still isn’t a better technique.